Each modified release tablet contains Trimetazidine Dihydrochloride BP 35 mg.
Metavas MR (Trimetazidine Dihydrochloride) is indicated in adults as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled by or intolerant to first-line antianginal therapies.
